In a marked shift toward competition-focused healthcare policy, the latest Executive Order on drug pricing reflects the Administration’s expanding use of antitrust tools to address high pharmaceutical costs. Framed around the “most-favored-nation” principle, this initiative is more than a pricing measure—it signals a broader regulatory agenda that targets market power and pricing disparities long shielded from traditional enforcement. Here’s what companies across the healthcare sector need to know.

In the absence of active enforcement by federal banking regulators, many financial institutions are choosing this moment to take a second look at their compliance policies and procedures. Recent administrative actions implicating access to financial services may particularly require financial institutions to reevaluate their Consumer Due Diligence (CDD) procedures and Consumer Identification Program (CIP).